These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 32945693

  • 21. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay.
    Niu H, Klem T, Yang J, Qiu Y, Pan L.
    J Immunol Methods; 2017 Jul; 446():30-36. PubMed ID: 28389174
    [Abstract] [Full Text] [Related]

  • 22. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.
    Kruzik A, Koppensteiner H, Fetahagic D, Hartlieb B, Dorn S, Romeder-Finger S, Coulibaly S, Weber A, Hoellriegl W, Horling FM, Scheiflinger F, Reipert BM, de la Rosa M.
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [Abstract] [Full Text] [Related]

  • 23. Selection of a Ligand-Binding Neutralizing Antibody Assay for Benralizumab: Comparison with an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cell-Based Assay.
    Wu Y, Akhgar A, Li JJ, Yu B, Chen C, Lee N, White WI, Roskos LK.
    AAPS J; 2018 Mar 14; 20(3):49. PubMed ID: 29541868
    [Abstract] [Full Text] [Related]

  • 24. Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence.
    Luong M, Wang Y, Berasi SP, Buhlmann JE, Yang H, Gorovits B.
    AAPS J; 2020 Mar 12; 22(2):56. PubMed ID: 32166588
    [Abstract] [Full Text] [Related]

  • 25. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?
    Jordan G, Staack RF.
    Bioanalysis; 2020 Jul 12; 12(14):1021-1031. PubMed ID: 32633539
    [Abstract] [Full Text] [Related]

  • 26. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.
    Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, Bowen MA, Spitz S, Jiang XR, Roskos LK, White WI.
    AAPS J; 2015 Nov 12; 17(6):1417-26. PubMed ID: 26205082
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Novel data analysis methods to overcome cut point challenges and enable comprehensive assessment of antidrug binding activity in confirmatory assays.
    Mikulskis A, Yeung D, Chen W, Mehta D, Amaravadi L.
    J Immunol Methods; 2013 Jun 28; 392(1-2):38-48. PubMed ID: 23541489
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.
    Mult Scler; 2011 Nov 28; 17(11):1333-40. PubMed ID: 21685230
    [Abstract] [Full Text] [Related]

  • 33. High ionic strength dissociation assay (HISDA) for high drug tolerant immunogenicity testing.
    Jordan G, Pöhler A, Guilhot F, Zaspel M, Staack RF.
    Bioanalysis; 2020 Jun 28; 12(12):857-866. PubMed ID: 32603603
    [Abstract] [Full Text] [Related]

  • 34. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference.
    McCutcheon KM, Quarmby V, Song A.
    J Immunol Methods; 2010 Jun 30; 358(1-2):35-45. PubMed ID: 20361968
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab.
    Xu W, Cummings J, Sank M, Juhel M, Li X, Gleason C, DeSilva BS, Dodge RW, Pillutla R.
    Bioanalysis; 2018 Aug 01; 10(16):1273-1287. PubMed ID: 29947549
    [Abstract] [Full Text] [Related]

  • 37. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK, Vainshtein I, Roskos LK, Chavez C, Sun B, Liang M.
    J Immunol Methods; 2016 Aug 01; 435():68-76. PubMed ID: 27220271
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H, Xu W, Titsch CA, Furlong MT, Dodge R, Voronin K, Allentoff A, Zeng J, Aubry AF, DeSilva BS, Arnold ME.
    Anal Chem; 2014 Mar 04; 86(5):2673-80. PubMed ID: 24506335
    [Abstract] [Full Text] [Related]

  • 40. Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.
    Goodman J, Cowen S, Devanarayan V, Egging D, Emrich T, Golob M, Kramer D, McNally J, Munday J, Nelson R, Pedras-Vasconcelos JA, Piironen T, Sickert D, Skibeli V, Fjording MS, Timmerman P.
    Bioanalysis; 2018 Feb 04; 10(4):197-204. PubMed ID: 29345496
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.